Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen; J S Johansen; Christian Dehlendorff; J S Larsen; K Osterlind; J Hansen; S E Nielsen; P Pfeiffer; Line Schmidt Tarpgaard; N H Holländer; N Keldsen; T F Hansen; B B Jensen; B V Jensen

doi:10.1093/annonc/mdt253

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen, J S Johansen, Christian Dehlendorff, J S Larsen, K Osterlind, J Hansen, S E Nielsen, P Pfeiffer, Line Schmidt Tarpgaard, N H Holländer, N Keldsen, T F Hansen, B B Jensen, B V Jensen

80 Citationer (Scopus)

Abstract

There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

Originalsprog	Engelsk
Tidsskrift	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind	24
Udgave nummer	10
Sider (fra-til)	2554-9
Antal sider	6
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdt253
Status	Udgivet - okt. 2013

Adgang til dokumentet

10.1093/annonc/mdt253

Citationsformater

Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Osterlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., Keldsen, N., Hansen, T. F., Jensen, B. B., & Jensen, B. V. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 24(10), 2554-9. https://doi.org/10.1093/annonc/mdt253

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. / Boisen, M K ; Johansen, J S; Dehlendorff, Christian et al.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 24, Nr. 10, 10.2013, s. 2554-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Boisen, MK , Johansen, JS, Dehlendorff, C, Larsen, JS, Osterlind, K, Hansen, J, Nielsen, SE, Pfeiffer, P, Tarpgaard, LS, Holländer, NH, Keldsen, N, Hansen, TF, Jensen, BB & Jensen, BV 2013, 'Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, bind 24, nr. 10, s. 2554-9. https://doi.org/10.1093/annonc/mdt253

@article{a33cd62cfb114a7eba702c3a9909cdeb,

title = "Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer",

abstract = "There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.",

author = "Boisen, {M K} and Johansen, {J S} and Christian Dehlendorff and Larsen, {J S} and K Osterlind and J Hansen and Nielsen, {S E} and P Pfeiffer and Tarpgaard, {Line Schmidt} and Holl{\"a}nder, {N H} and N Keldsen and Hansen, {T F} and Jensen, {B B} and Jensen, {B V}",

year = "2013",

month = oct,

doi = "10.1093/annonc/mdt253",

language = "English",

volume = "24",

pages = "2554--9",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

AU - Boisen, M K

AU - Johansen, J S

AU - Dehlendorff, Christian

AU - Larsen, J S

AU - Osterlind, K

AU - Hansen, J

AU - Nielsen, S E

AU - Pfeiffer, P

AU - Tarpgaard, Line Schmidt

AU - Holländer, N H

AU - Keldsen, N

AU - Hansen, T F

AU - Jensen, B B

AU - Jensen, B V

PY - 2013/10

Y1 - 2013/10

N2 - There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

AB - There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.

U2 - 10.1093/annonc/mdt253

DO - 10.1093/annonc/mdt253

M3 - Journal article

C2 - 23864097

SN - 0923-7534

VL - 24

SP - 2554

EP - 2559

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 10

ER -

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater